Drug Trial Radar · NCT06173518
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Nov 16, 2023
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Autolus LimitedIndustry
- Sponsor type
- Industry
- First posted
- Dec 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B NHL).
Conditions
- Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Interventions
AUTO1Biological
Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with anti-CD19 chimeric antigen receptor (CAR) T cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: Up to 24 months
- Incidence and duration of severe hypogammaglobulinemiaTime frame: Up to 24 months
- Proportion of pediatric participants with r/r B ALL at screening who achieve complete remission (CR) within 3 months of obe-cel infusion per Independent Response Review Committee (IRRC) assessmentTime frame: 3 months
Locations
15 sites in 3 countries. Site status is shown where the registry gives one.
Children's Hospital Los Angeles
Los Angeles, California · Recruiting
Lucile Packard Children's Hospital, Stanford University
Palo Alto, California · Recruiting
Children's Hospital Colorado
Aurora, Colorado · Recruiting
Arthur M Blank Hospital
Atlanta, Georgia · Recruiting
Lurie Children's Hospital
Chicago, Illinois · Recruiting
Cincinnati Children's Hospital
Cincinnati, Ohio · Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
Methodist Children's Hospital
San Antonio, Texas · Recruiting
Primary Children's Hospital
Salt Lake City, Utah · Recruiting
Seattle Children's Hospital
Seattle, Washington · Recruiting
Hospital Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital Nino Jesus
Madrid, Spain · Recruiting
Great Ormond Street Hospital for Children NHS Foundation Trust
London, United Kingdom · Recruiting
Royal Manchester Children's Hospital
Manchester, United Kingdom · Recruiting
Great North Children's Hospital
Newcastle upon Tyne, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.